$82.04+0.43 (+0.53%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$81.98−0.06 (−0.07%)
After hours: Nov 17, 2026, 6:23 PM ET
Dexcom (DXCM) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~17.5%/yr (FY21→FY25), net margin 17.9%, and free cash flow (~$1.1B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲15.6%
4,662.0
FY21→FY25CAGR +17.5%/yr
Net income ($M)▲45.1%
836.3
FY21→FY25CAGR +40.1%/yr
Free cash flow ($M)▲70.8%
1,077.2
FY21→FY25CAGR +112.0%/yr
Diluted EPS▲47.2%
2.09
buyback-liftedCAGR +40.9%/yr
What the receipts whisper · what a headline number hides
Share count
−5.4%
428.8mn → 405.5mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$363.5M
steady at 7.8% of revenue (+1.3% YoY).
Returns vs FCF
46%
$0.5B returned vs $1.1B of FCF in FY25. Buybacks covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
18¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 68.6% → 60.1%. Net margin 17.9% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 5,104,400.0 | 4,662,000.0 | 4,033,000.0 | 3,622,300.0 | 2,909,800.0 | 2,448,500.0 | ▲15.6% | +17.5% |
Cost of revenue | 1,867,000.0 | 1,860,100.0 | 1,594,800.0 | 1,333,400.0 | 1,026,700.0 | 768,000.0 | ▲16.6% | +24.8% |
Gross profit | 3,237,400.0 | 2,801,900.0 | 2,438,200.0 | 2,288,900.0 | 1,883,100.0 | 1,680,500.0 | ▲14.9% | +13.6% |
Research & development | 608,100.0 | 599,100.0 | 552,400.0 | 505,800.0 | 484,200.0 | 604,200.0 | ▲8.5% | −0.2% |
Selling, general & admin | 1,405,500.0 | 1,291,000.0 | 1,285,800.0 | 1,185,400.0 | 1,007,700.0 | 810,500.0 | ▲0.4% | +12.3% |
Total operating expenses | 2,013,600.0 | 1,890,100.0 | 1,838,200.0 | 1,691,200.0 | 1,491,900.0 | 1,414,700.0 | ▲2.8% | +7.5% |
Operating incomefeeds ROC rank | 1,223,800.0 | 911,800.0 | 600,000.0 | 597,700.0 | 391,200.0 | 265,800.0 | ▲52.0% | +36.1% |
Other income, net | 38,600.0 | 176,600.0 | 109,000.0 | 112,700.0 | −400.0 | −9,000.0 | — | — |
Pretax income | 1,262,400.0 | 1,088,400.0 | 709,000.0 | 710,400.0 | 390,800.0 | 256,800.0 | ▲53.5% | +43.5% |
Income tax | 271,400.0 | 252,100.0 | 132,800.0 | 168,900.0 | 49,600.0 | 39,900.0 | ▲89.8% | +58.5% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 991,000.0 | 836,300.0 | 576,200.0 | 541,500.0 | 341,200.0 | 216,900.0 | ▲45.1% | +40.1% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 2.54 | 2.09 | 1.42 | 1.30 | 0.82 | 0.53 | ▲47.2% | +40.9% |
Diluted shares (mn) | 383.50 | 405.50 | 412.70 | 425.50 | 427.50 | 428.80 | ▼1.7% | −1.4% |
| Margins | ||||||||
Gross margin45th pct in Healthcare | 63.4% | 60.1% | 60.5% | 63.2% | 64.7% | 68.6% | ▼0.4pp | −8.5pp |
Operating margin | 24.0% | 19.6% | 14.9% | 16.5% | 13.4% | 10.9% | ▲4.7pp | +8.7pp |
Net margin83rd pct in Healthcare | 19.4% | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | ▲3.7pp | +9.1pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Dexcom's revenue last fiscal year?
Dexcom reported revenue of $4,662.0M in fiscal 2025, up 15.6% from fiscal 2024.
What was Dexcom's net income?
Dexcom reported net income of $836.3M in fiscal 2025, a net margin of 17.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

